DekaBank Deutsche Girozentrale Has $219.51 Million Stock Holdings in Stryker Co. (NYSE:SYK)

DekaBank Deutsche Girozentrale lifted its position in shares of Stryker Co. (NYSE:SYK) by 3.9% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 735,660 shares of the medical technology company’s stock after buying an additional 27,868 shares during the quarter. DekaBank Deutsche Girozentrale owned about 0.19% of Stryker worth $219,506,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Fairfield Bush & CO. acquired a new stake in Stryker in the first quarter valued at approximately $131,000. Dimensional Fund Advisors LP boosted its stake in shares of Stryker by 1.4% during the first quarter. Dimensional Fund Advisors LP now owns 673,924 shares of the medical technology company’s stock valued at $180,182,000 after purchasing an additional 9,026 shares in the last quarter. Prudential PLC bought a new stake in shares of Stryker during the first quarter worth about $1,444,000. Sequoia Financial Advisors LLC increased its stake in shares of Stryker by 21.6% in the first quarter. Sequoia Financial Advisors LLC now owns 3,056 shares of the medical technology company’s stock valued at $817,000 after buying an additional 543 shares during the period. Finally, Zions Bancorporation N.A. raised its stake in shares of Stryker by 9.2% during the first quarter. Zions Bancorporation N.A. now owns 3,140 shares of the medical technology company’s stock valued at $839,000 after acquiring an additional 265 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Wells Fargo & Company lifted their price objective on Stryker from $336.00 to $364.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 31st. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Citigroup increased their price target on Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a research report on Wednesday. Roth Mkm lifted their target price on Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Finally, Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and increased their price target for the company from $315.00 to $360.00 in a research report on Wednesday, January 31st. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $335.27.

Stryker Price Performance

Shares of NYSE:SYK traded up $3.64 during trading on Friday, reaching $351.02. The company had a trading volume of 677,501 shares, compared to its average volume of 1,015,425. The company has a fifty day moving average of $349.09 and a two-hundred day moving average of $308.42. Stryker Co. has a 12 month low of $249.98 and a 12 month high of $361.41. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $133.55 billion, a P/E ratio of 42.55, a price-to-earnings-growth ratio of 2.83 and a beta of 0.89.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, beating the consensus estimate of $3.27 by $0.19. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The company had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same quarter last year, the firm earned $3.00 EPS. The firm’s quarterly revenue was up 11.8% compared to the same quarter last year. Equities research analysts forecast that Stryker Co. will post 11.86 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a $0.80 dividend. This represents a $3.20 annualized dividend and a yield of 0.91%. The ex-dividend date is Wednesday, March 27th. Stryker’s dividend payout ratio (DPR) is currently 38.79%.

Insider Activity

In related news, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the transaction, the director now directly owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the transaction, the director now directly owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 201,146 shares of Stryker stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the completion of the sale, the director now directly owns 3,755,128 shares of the company’s stock, valued at approximately $1,287,633,391.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 212,109 shares of company stock valued at $72,845,768. Corporate insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.